首页> 美国卫生研究院文献>Scientific Reports >Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
【2h】

Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers

机译:中国妇科癌症患者的分子谱和肿瘤突变负担分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The goal of this work was to investigate the tumor mutational burden (TMB) in Chinese patients with gynecologic cancer. In total, 117 patients with gynecologic cancers were included in this study. Both tumor DNA and paired blood cell genomic DNA were isolated from formalin-fixed paraffin-embedded (FFPE) specimens and blood samples, and next-generation sequencing was performed to identify somatic mutations. TP53, PTEN, ARID1A, and PIK3CA alterations were significantly different in various types of gynecologic cancers (p = 0.001, 1.15E-07, 0.004, and 0.009, respectively). The median TMB of all 117 gynecologic tumor specimens was 0.37 mutations/Mb, with a range of 0–41.45 mutations/Mb. Despite the lack of significant difference, endometrial cancer cases had a higher median TMB than cervical and ovarian cancer cases. Younger gynecologic cancer patients (age <40 years) had a significantly lower TMB than older patients (age ≥40 years) (p = 0.04). In addition, TMB was significantly increased with increasing clinical stage of disease (p = 0.001). PTEN alterations were commonly observed in patients with a moderate to high TMB (n = 8, 38.10%, p = 9.95E-04). Although limited by sample size, all of the patients with TSC2 (n = 3, p = 3.83E-11) or POLE (n = 2, p = 0.005) mutations had a moderate to high TMB. Further large-scale, prospective studies are needed to validate our findings.
机译:这项工作的目的是调查中国妇科癌症患者的肿瘤突变负担(TMB)。本研究共纳入117例妇科癌症患者。从福尔马林固定石蜡包埋(FFPE)标本和血液样本中分离出肿瘤DNA和成对的血细胞基因组DNA,并进行了下一代测序以鉴定体细胞突变。 TP53,PTEN,ARID1A和PIK3CA改变在各种类型的妇科癌症中有显着差异(分别为p = 0.001、1.15E-07、0.004和0.009)。所有117例妇科肿瘤标本的中位TMB为0.37突变/ Mb,范围为0–41.45突变/ Mb。尽管没有显着差异,但子宫内膜癌病例的TMB中位数高于宫颈癌和卵巢癌病例。年轻的妇科癌症患者(<40岁)的TMB明显低于年长的患者(≥40岁)(p = 0.04)。另外,随着疾病临床阶段的增加,TMB显着增加(p = 0.001)。在中度至高TMB患者中通常观察到PTEN改变(n = 8,38.10%,p = 9.95E-04)。尽管受样本量的限制,但所有具有TSC2(n = 3,p = 3.83E-11)或POLE(n = 2,p = 0.005)突变的患者均具有中度至高TMB。需要进一步的大规模前瞻性研究来验证我们的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号